Clinical Report: Effects of Drug-Coated Balloons on Stenosis of the LAD
Overview
This study investigates the clinical outcomes of drug-coated balloons (DCBs) versus drug-eluting stents (DES) in patients with left anterior descending artery (LAD) stenosis proximal to myocardial bridges. The findings indicate no significant difference in major adverse cardiac events (MACEs) between the two treatment modalities over a median follow-up of 507 days.
Background
Myocardial bridges (MB) are congenital anomalies that can lead to significant coronary artery stenosis, particularly in the LAD. Treatment options for stenosis in this anatomical context are limited, with stent implantation being the primary intervention. Drug-coated balloons (DCBs) offer a potential alternative, but their efficacy in this specific setting has not been well established.
Data Highlights
No statistically significant difference in MACE-free survival was observed between DCB and DES groups (73.96% vs. 82.49%, log-rank P = 0.678). Cox regression analysis showed no significant difference in MACEs (HR = 1.58, P = 0.383).
Key Findings
No significant benefit of DCB over DES for treating LAD stenosis proximal to MB.
73.96% MACE-free survival in the DCB group versus 82.49% in the DES group.
Median follow-up duration was 507 days.
Sample size was limited, indicating preliminary results.
Further larger prospective studies are needed to validate findings.
Clinical Implications
The results suggest that DCB may not be a reasonable alternative to DES for patients with LAD stenosis proximal to MB. Clinicians should consider these findings when selecting treatment strategies for this patient population.
Conclusion
This exploratory analysis indicates no significant advantage of DCB over DES in the specified clinical context. Further research is necessary to explore the role of DCB in treating LAD stenosis proximal to myocardial bridges.
